Article Details
Retrieved on: 2018-03-19 08:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Roche showed the value it places on real-world cancer evidence when it struck a $1.9bn (£1.3bn) deal to acquire oncology EHR provider <b>Flatiron Health</b>. The takeover was driven by a belief that “regulatory-grade real-world evidence is a key ingredient to accelerate the development of, and access to, ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here